Roth MKM Sticks to Their Hold Rating for Mattel (MAT)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Handler covers the Communication Services sector, focusing on stocks such as Cinemark Holdings, Electronic Arts, and IMAX. According to TipRanks, Handler has an average return of 13.2% and a 63.69% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mattel with a $23.56 average price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Why LVMH Stock (MC) Is Catching Wall Street's Attention
French luxury products company LVMH Moët Hennessy Louis Vuitton, or LVMH (FR:MC) (LVMUY), is drawing strong support from Wall Street as several analysts maintain their Buy ratings. The recent wave of bullish ratings came despite the company reporting a challenging Q2 for 2025. Year-to-date, MC stock has declined more than 25%, reflecting broader market pressures on the luxury sector. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. LVMH is a European fashion house known for its iconic luxury brands like Louis Vuitton, Sephora, Fendi, Bulgari, and more. The company is primarily listed on the Euronext Paris exchange but also trades over-the-counter (OTC) in the U.S. LVMH Q2 2025 Results Overview In Q2, LVMH's core fashion and leather goods segment saw a sharp drop in sales, falling 9% year-over-year. The decline was larger than analyst expectations and marked the steepest drop among all of LVMH's business segments. This reflected continued weak demand for luxury products amid rising prices and economic uncertainty. Overall, LVMH's net profit dropped 22% year-over-year in the first half, while operating profit fell 15%. Looking ahead, the company warned that a full recovery will take time as it faces an industry-wide slowdown, with softer demand from Chinese shoppers and ongoing uncertainty among U.S. consumers. Wall Street Analysts Stay Bullish Despite the lackluster results, analysts have maintained their buy ratings on MC stock. Four-star-rated analyst Luca Solca at Bernstein reiterated his Buy rating on MC stock at a price target of €600, implying more than a 30% growth rate. Sola stated that the recent results showed effective cost control despite weak demand. He added that focus will now shift to how the company tackles its challenges and the potential impact on its business in the second half of the year. Likewise, RBC Capital's analyst Piral Dadhania maintained his Buy rating. He noted that while LVMH's recent underperformance presents a 'fairly attractive' risk/reward, it is supported by an expected near-term boost in Fashion & Leather Goods from easier comparisons. Is LVMH Stock a Good Buy? Overall, MC stock has received a Moderate Buy rating on TipRanks, backed by a total of 19 recommendations from analysts. It includes 10 Buys and nine Holds assigned in the last three months. The LVMH share price target is €565.14, which is 20% higher than the current trading level.
Yahoo
3 hours ago
- Yahoo
Solar, biotech, and health insurance stocks are rising on Friday: here's why
Solar, biotech, and health insurance stocks are rising on Friday: here's why originally appeared on TheStreet. After a whirlwind week of economic data, stocks are taking a chill pill on Friday, ending off the week on a low note. The Russell 2000, Nasdaq Composite, and S&P 500 are down 0.44%, 0.41%, and 0.16% respectively. The Dow is the only major U.S. index in the green for the moment, up 0.21%. At face, those moves aren't very dramatic. On Tuesday, U.S. equities jumped dramatically after the release of the Consumer Price Index (CPI) showed that inflation moderated in July, with the growth-centric Russell 2000 soaring nearly 3%. But by Thursday, things were all topsy-turvy, with the release of the Producer Price Index (PPI). Both elicited much more dramatic responses. Still, below the top-line figures we see at the top of the market, there's always stories in the stock market. Even today, a quiet Friday, there are stocks making big moves. In fact, many of today's biggest movers come from the solar, biotech, and health insurance business. But why? Let's start with the reason why the Dow is up today: UnitedHealth unites health insurers; lifts Dow If you haven't seen the year-to-date chart on health insurer UnitedHealth () , you've gotta see it. Back in April, the stock looked like it might be building towards an all-time high. Then, next thing you know, it was the worst performer in the Dow (and one of the worst in the S&P 500.) Poor earnings results, a weaker outlook, and few hopes for a quick recovery have weighed on the stock. At one point, it had lost half of its value on the year. But today, it's scoring a bid from a value-minded investors we all know and love: Berkshire Hathaway's Warren Buffett. As such, it's up 14% today, almost single-handedly lifting the Dow. That's not anecdote, either: UnitedHealth is contributing 236 of the Dow's points as of this writing. If it weren't part of the index, the Dow would be down 95 points today, per our very own Charley Blaine. The confidence is also helping lift similarly-situated health insurers, who have been experiencing similar struggles in the face of government budget cuts and higher health care utilization. Centene () (+6%), Oscar Health () (+5.8%), and Elevance Health () (+5.5%) are all following UnitedHealth onward and upward today. Pharma stocks jump Small-caps might be down, but pharma and biotech stocks are up today... again! For the unacquainted, the SPDR S&P Biotech ETF () and the iShares Biotechnology ETF () are up 6.2% and 5.2% this week respectively (mind you, those are intraday figures.) That's a kind premium on these battered-down stocks, especially when you compare it to the Russell's 3% return over the same period. So who's leading the leaders today? Arrowhead Pharmaceuticals (+7%), Moderna (+7%), and Sarepta Therapeutics (+6.3%). Ironically, all firms that have faced their fair share of trial and tribulation recently. Sarepta has faced FDA scrutiny over its gene therapy for Duchenne muscular dystrophy, forcing it to sell shares of Arrowhead, in which it was a sizable investor, to shore up its cash position. And Moderna? Well, in case you didn't know, this administration isn't terribly enthused about mRNA vaccines for any number of reasons. Still, the company has an incredibly robust portfolio which might make the U.S. pay for, in every sense of the definition, turning their nose up at them. Don't get us wrong, there are some sinkers too, like Tonix Pharmaceuticals (-13.8%), which is atop the trending charts on investing social media platform Stocktwits this P.M., cooling down after the FDA approval of their new fibromyalgia drug. Even that's good news, really! Of course, if you zoom out, there have been fantastic returns out of bio land this year in general. This is just another Friday, really. Not only are large pharma firms like Sanofi () and Merck () rolling up wads of cash and heading to M&A Station, but some smaller names like have been breaking out. Let the largest holdings in the XBI speak for themselves: Alnylam () (+91% year-to-date), Insmed () (+80%), Halozyme () (+39%). Impressive might be an understatement. It's not just sunny in health care land There's still money to be made outside of health care, though. Today, shares of solar stocks like Sunrun () (+32%), First Solar () (+13%), Nextracker () (+12%), and Enphase Energy () (+12%) are higher. What's charging up these solar names? Sunrun's fantastic Q2 earnings, which dropped this morning. It revealed that the company's profits more than doubled year-over-year, while revenues blew past expectations. Sunrun's big run comes just a few weeks after First Solar was first to sound off about the fast growth in the solar market. It raised its guidance across the board after a fantastic quarter, giving investors a 'heads up' that it wasn't all so dreary in the clean energy sector, even if the Federal Government is indeed paling back tax credits and incentives for these sorts of energy investments (it plans to direct that money to expendable energy sources like natural gas, oil, and coal.) The Invesco Solar ETF () is up 10.2% intraday; the iShares Global Clean Energy ETF () is up nearly 4%.Solar, biotech, and health insurance stocks are rising on Friday: here's why first appeared on TheStreet on Aug 15, 2025 This story was originally reported by TheStreet on Aug 15, 2025, where it first appeared. Sign in to access your portfolio
Miami Herald
5 hours ago
- Miami Herald
Starbucks rival continues its US expansion
Whether you're a coffee lover or not, Starbucks is nearly impossible to ignore. With over 40,000 locations in 80 countries, it has become the most recognizable name in coffee worldwide; chances are, almost everyone has tried something from its menu at least once. However, Starbucks has experienced a noticeable decline in recent years. Sales are down, store traffic has slowed, and concerns about the company's long-term growth have prompted a major turnaround strategy to revive its business. Don't miss the move: Subscribe to TheStreet's free daily newsletter While Starbucks still dominates the market, smaller chains like Dutch Bros (BROS) , Scooter's Coffee, and 7 Brew Coffee have been gaining traction, steadily growing their customer bases. Now, Starbucks faces perhaps its most significant challenge yet. A powerful international rival has entered the U.S. market, threatening its position as a coffee leader. Related: Starbucks faces huge new rival Founded in 2017 in Beijing, Luckin Coffee (LKNCY) entered the coffee scene 46 years after Starbucks (SBUX) launched, and has already surpassed expectations. With over 22,000 stores, it's now the largest coffee chain in China, overshadowing Starbucks in that market. Although relatively unknown to Americans, Luckin Coffee immediately caught people's attention when it opened its first stores in New York City on June 30. It debuted two locations, one at 55 Broadway and another at 800 6th Ave., introducing its blue-and-white deer logo to the U.S. Image source:Luckin Coffee is known for its high-quality coffee and wide range of menu options at affordable prices. However, due to economic and currency differences, prices at its U.S. locations are understandably higher than in Asia. Starbucks has faced backlash over the last few months for raising its prices. In response to criticism, it simplified its menu and eliminated extra charges, a timely move that coincides with its rival's arrival in the U.S. Related: Starbucks' huge new rival opens first US stores When comparing their menus, Luckin Coffee clearly acknowledges Starbucks as a competitor. Both chains carry handcrafted coffee beverages, frappes, matcha drinks, and refreshers. Their prices are also very similar, with a 16-ounce drip coffee costing $3.45. And so far, U.S. consumers seem intrigued to give Luckin Coffee a chance. During its opening week, lines were out the door, with many people eager to try the new coffee shop in town. Keeping the momentum, Luckin Coffee has wasted no time expanding into the U.S. In a recent Instagram post, the company teased the grand opening of its third location in New York City, hinting that the new store will be "steps away from Columbus Circle" and asking people to guess the exact location. This sparked a wave of fans quickly flooding the comments section, with many commenting "901 8th Ave." More Food News: After bankruptcy, Starbucks rival plans aggressive expansionPizza Hut menu adds a completely new type of pizzaHershey teams up with Costco to make a dream candy combo The Chinese coffee chain also posted a picture to its Instagram story revealing the outside of the new coffee shop, which appears completed. Although Luckin Coffee has yet to provide an official date for the grand opening of its new location, it claims it will be opening very soon. To promote it, Luckin Coffee launched a scavenger hunt that will end on August 18 and allows participants to win prizes and free drinks. This suggests that the third store could open on Monday Aug. 18. Related: Starbucks plans major change to how it adds new menu items The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
